Published in Muscle Nerve on March 01, 2008
Rapamycin reverses elevated mTORC1 signaling in lamin A/C-deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med (2012) 1.98
Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One (2009) 1.98
Redundancy of myostatin and growth/differentiation factor 11 function. BMC Dev Biol (2009) 1.56
Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve (2009) 1.34
Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle (2011) 1.28
Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Rev Mol Med (2009) 1.22
Nitrosative stress elicited by nNOSµ delocalization inhibits muscle force in dystrophin-null mice. J Pathol (2010) 1.20
Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice. PLoS One (2010) 1.10
Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice. Hum Mol Genet (2009) 1.09
Wasting mechanisms in muscular dystrophy. Int J Biochem Cell Biol (2013) 1.07
Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve (2010) 1.03
Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther (2010) 1.01
Relation between extent of myostatin depletion and muscle growth in mature mice. Am J Physiol Endocrinol Metab (2009) 0.96
Endurance exercise training in myostatin null mice. Muscle Nerve (2010) 0.92
COL6A3 protein deficiency in mice leads to muscle and tendon defects similar to human collagen VI congenital muscular dystrophy. J Biol Chem (2013) 0.91
Small RNA-Mediated Epigenetic Myostatin Silencing. Mol Ther Nucleic Acids (2012) 0.89
Myostatin is upregulated following stress in an Erk-dependent manner and negatively regulates cardiomyocyte growth in culture and in a mouse model. PLoS One (2010) 0.87
Novel therapeutic approaches for inclusion body myositis. Curr Opin Rheumatol (2010) 0.85
Long-term systemic myostatin inhibition via liver-targeted gene transfer in golden retriever muscular dystrophy. Hum Gene Ther (2011) 0.85
Curcumin and muscle wasting: a new role for an old drug? Nutrition (2008) 0.83
A mouse model for dominant collagen VI disorders: heterozygous deletion of Col6a3 Exon 16. J Biol Chem (2014) 0.83
Systemic administration of follistatin288 increases muscle mass and reduces fat accumulation in mice. Sci Rep (2013) 0.79
Ongoing developments in sporadic inclusion body myositis. Curr Rheumatol Rep (2014) 0.78
Pharmacology of manipulating lean body mass. Clin Exp Pharmacol Physiol (2015) 0.78
Limb-girdle muscular dystrophies: where next after six decades from the first proposal (Review). Mol Med Rep (2014) 0.78
Therapeutic possibilities in the autosomal recessive limb-girdle muscular dystrophies. Neurotherapeutics (2008) 0.77
Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1. Dig Dis Sci (2016) 0.76
Pleiotropic Genes Affecting Carcass Traits in Bos indicus (Nellore) Cattle Are Modulators of Growth. PLoS One (2016) 0.76
Prospect of gene therapy for cardiomyopathy in hereditary muscular dystrophy. Expert Opin Orphan Drugs (2015) 0.75
Functional improvement of dystrophic muscle by myostatin blockade. Nature (2002) 5.10
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Spontaneous coronary vasospasm in KATP mutant mice arises from a smooth muscle-extrinsic process. Circ Res (2006) 2.64
Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am J Pathol (2005) 2.45
The dystrophin glycoprotein complex: signaling strength and integrity for the sarcolemma. Circ Res (2004) 2.29
Nesprin-1alpha self-associates and binds directly to emerin and lamin A in vitro. FEBS Lett (2002) 2.24
Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J (2005) 2.14
Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 K(ATP) channels. J Clin Invest (2002) 2.11
Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu Rev Physiol (2009) 2.03
Myne-1, a spectrin repeat transmembrane protein of the myocyte inner nuclear membrane, interacts with lamin A/C. J Cell Sci (2002) 2.02
Population-based variation in cardiomyopathy genes. Circ Cardiovasc Genet (2012) 2.00
Normal myoblast fusion requires myoferlin. Development (2005) 1.97
Disruption of nesprin-1 produces an Emery Dreifuss muscular dystrophy-like phenotype in mice. Hum Mol Genet (2008) 1.83
Familial dilated cardiomyopathy caused by an alpha-tropomyosin mutation: the distinctive natural history of sarcomeric dilated cardiomyopathy. J Am Coll Cardiol (2010) 1.83
The genetics of dilated cardiomyopathy. Curr Opin Cardiol (2010) 1.76
Calcium-sensitive phospholipid binding properties of normal and mutant ferlin C2 domains. J Biol Chem (2002) 1.73
Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest (2009) 1.67
Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol (2006) 1.64
LTBP4 genotype predicts age of ambulatory loss in Duchenne muscular dystrophy. Ann Neurol (2013) 1.63
Functional nitric oxide synthase mislocalization in cardiomyopathy. J Mol Cell Cardiol (2004) 1.58
Nesprin-1 mutations in human and murine cardiomyopathy. J Mol Cell Cardiol (2009) 1.48
The von Hippel-Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice. J Clin Invest (2010) 1.46
The endocytic recycling protein EHD2 interacts with myoferlin to regulate myoblast fusion. J Biol Chem (2008) 1.45
Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc Natl Acad Sci U S A (2004) 1.38
Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. J Mol Med (Berl) (2003) 1.38
S100A12 mediates aortic wall remodeling and aortic aneurysm. Circ Res (2009) 1.36
Genetic background influences muscular dystrophy. Neuromuscul Disord (2005) 1.34
Nesprin-1alpha contributes to the targeting of mAKAP to the cardiac myocyte nuclear envelope. Exp Cell Res (2005) 1.34
S100A12 in vascular smooth muscle accelerates vascular calcification in apolipoprotein E-null mice by activating an osteogenic gene regulatory program. Arterioscler Thromb Vasc Biol (2010) 1.32
Consequences of disrupting the dystrophin-sarcoglycan complex in cardiac and skeletal myopathy. Trends Cardiovasc Med (2007) 1.30
Reduced life span with heart and muscle dysfunction in Drosophila sarcoglycan mutants. Hum Mol Genet (2007) 1.28
Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A (2010) 1.24
Transplanted hematopoietic stem cells demonstrate impaired sarcoglycan expression after engraftment into cardiac and skeletal muscle. J Clin Invest (2004) 1.23
Deletion of periostin reduces muscular dystrophy and fibrosis in mice by modulating the transforming growth factor-β pathway. Proc Natl Acad Sci U S A (2012) 1.23
Cardiac assessment in duchenne and becker muscular dystrophies. Curr Heart Fail Rep (2010) 1.21
Repairing the tears: dysferlin in muscle membrane repair. Trends Mol Med (2003) 1.21
Genetic compensation for sarcoglycan loss by integrin alpha7beta1 in muscle. J Cell Sci (2004) 1.19
Myoferlin regulates vascular endothelial growth factor receptor-2 stability and function. J Biol Chem (2007) 1.19
Impaired muscle growth and response to insulin-like growth factor 1 in dysferlin-mediated muscular dystrophy. Hum Mol Genet (2010) 1.19
Expression profiling reveals metabolic and structural components of extraocular muscles. Physiol Genomics (2002) 1.17
Smooth muscle cell-extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. J Clin Invest (2004) 1.14
Nesprins, but not sun proteins, switch isoforms at the nuclear envelope during muscle development. Dev Dyn (2010) 1.13
Sulfonylurea receptor-dependent and -independent pathways mediate vasodilation induced by ATP-sensitive K+ channel openers. Mol Pharmacol (2008) 1.13
Mice lacking sulfonylurea receptor 2 (SUR2) ATP-sensitive potassium channels are resistant to acute cardiovascular stress. J Mol Cell Cardiol (2007) 1.13
Cardiac sulfonylurea receptor short form-based channels confer a glibenclamide-insensitive KATP activity. J Mol Cell Cardiol (2007) 1.12
Molecular identification and functional characterization of a mitochondrial sulfonylurea receptor 2 splice variant generated by intraexonic splicing. Circ Res (2009) 1.12
Combination of peptide OFFGEL fractionation and label-free quantitation facilitated proteomics profiling of extraocular muscle. Proteomics (2007) 1.12
SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy. Hum Mol Genet (2010) 1.10
Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy. Am J Pathol (2009) 1.08
Sarcomere mutations in cardiomyopathy with left ventricular hypertrabeculation. Circ Cardiovasc Genet (2009) 1.07
Advocacy: yes we can. J Clin Invest (2012) 1.07
Erythrocytosis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J Biol Chem (2013) 1.07
Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc Natl Acad Sci U S A (2014) 1.07
Gene expression and molecular changes in cerebral arteries following subarachnoid hemorrhage in the rat. J Neurosurg (2006) 1.06
TBX5 drives Scn5a expression to regulate cardiac conduction system function. J Clin Invest (2012) 1.06
Loss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles. J Clin Invest (2011) 1.05
Distinct genetic regions modify specific muscle groups in muscular dystrophy. Physiol Genomics (2010) 1.05
Endocytic recycling proteins EHD1 and EHD2 interact with fer-1-like-5 (Fer1L5) and mediate myoblast fusion. J Biol Chem (2010) 1.05
Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J Am Coll Cardiol (2006) 1.04
Definition of the unique human extraocular muscle allotype by expression profiling. Physiol Genomics (2005) 1.04
Identification of the A3 adenosine receptor in rat retinal ganglion cells. Mol Vis (2006) 1.04
Mechanisms of muscle weakness in muscular dystrophy. J Gen Physiol (2010) 1.03
Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition. PLoS One (2010) 1.02
Quantitative proteomics profiling of sarcomere associated proteins in limb and extraocular muscle allotypes. Mol Cell Proteomics (2007) 1.01
Processing and assembly of the dystrophin glycoprotein complex. Traffic (2007) 1.01
Emery-Dreifuss muscular dystrophy. Handb Clin Neurol (2011) 1.01
Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Hum Mol Genet (2002) 1.01
Form-deprivation myopia in chick induces limited changes in retinal gene expression. Invest Ophthalmol Vis Sci (2007) 1.00
Genetic disruption of calcineurin improves skeletal muscle pathology and cardiac disease in a mouse model of limb-girdle muscular dystrophy. J Biol Chem (2007) 1.00
Myoferlin is required for insulin-like growth factor response and muscle growth. FASEB J (2009) 0.99
Ferlin proteins in myoblast fusion and muscle growth. Curr Top Dev Biol (2011) 0.98
Hydrogen sulfide dilates cerebral arterioles by activating smooth muscle cell plasma membrane KATP channels. Am J Physiol Heart Circ Physiol (2011) 0.96
Lamin A/C truncation in dilated cardiomyopathy with conduction disease. BMC Med Genet (2003) 0.96
S100A12 expression in thoracic aortic aneurysm is associated with increased risk of dissection and perioperative complications. J Am Coll Cardiol (2012) 0.95
Duchenne muscular dystrophy: how bad is the heart? Heart (2008) 0.95
Modifying muscular dystrophy through transforming growth factor-β. FEBS J (2013) 0.95
Pharmacology of myopia and potential role for intrinsic retinal circadian rhythms. Exp Eye Res (2013) 0.95
Chronic hypoxia impairs muscle function in the Drosophila model of Duchenne's muscular dystrophy (DMD). PLoS One (2010) 0.95
Genetic pathways of vascular calcification. Trends Cardiovasc Med (2012) 0.94
Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. FASEB J (2002) 0.94
Nuclear sequestration of delta-sarcoglycan disrupts the nuclear localization of lamin A/C and emerin in cardiomyocytes. Hum Mol Genet (2006) 0.93
Exon-skipping therapy: a roadblock, detour, or bump in the road? Sci Transl Med (2014) 0.92
Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening. PLoS One (2011) 0.91
Genetic modifiers of muscular dystrophy: implications for therapy. Biochim Biophys Acta (2006) 0.91
Secondary coronary artery vasospasm promotes cardiomyopathy progression. Am J Pathol (2004) 0.91
Image defocus and altered retinal gene expression in chick: clues to the pathogenesis of ametropia. Invest Ophthalmol Vis Sci (2011) 0.91
COL6A3 protein deficiency in mice leads to muscle and tendon defects similar to human collagen VI congenital muscular dystrophy. J Biol Chem (2013) 0.91
The superhealing MRL background improves muscular dystrophy. Skelet Muscle (2012) 0.90
Pretreatment with a soluble activin type IIB receptor/Fc fusion protein improves hypoxia-induced muscle dysfunction. Am J Physiol Regul Integr Comp Physiol (2009) 0.90
Gene expression, chromosome position and lamin A/C mutations. Nucleus (2011) 0.90
A knock-in mouse model of human PHD2 gene-associated erythrocytosis establishes a haploinsufficiency mechanism. J Biol Chem (2013) 0.89
Translational regulation of utrophin by miRNAs. PLoS One (2011) 0.88
Distinctive patterns of microRNA expression in extraocular muscles. Physiol Genomics (2010) 0.88
Sarcoglycans in vascular smooth and striated muscle. Trends Cardiovasc Med (2003) 0.88
Myoferlin regulation by NFAT in muscle injury, regeneration and repair. J Cell Sci (2010) 0.87
Impaired exercise tolerance and skeletal muscle myopathy in sulfonylurea receptor-2 mutant mice. Am J Physiol Regul Integr Comp Physiol (2009) 0.87
Gene profiling in experimental models of eye growth: clues to myopia pathogenesis. Vision Res (2010) 0.87
Modifier genes and their effect on Duchenne muscular dystrophy. Curr Opin Neurol (2015) 0.87
Modifiers of heart and muscle function: where genetics meets physiology. Exp Physiol (2013) 0.86
Sarcomere mutations in cardiomyopathy, noncompaction, and the developing heart. Circulation (2008) 0.86